GLENMARK - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

GLENMARK · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Glenn Saldanha · Listing date: Feb. 9, 2000 · Employees: 10964 · Mumbai · http://www.glenmarkpharma.com

Stock Price vs Company Growth

3.0%

3.9%

12.5%

19.4%

64.7%

33.8%

10y

11.6%

all

11.3%

🤔 How to analyze this graph?

Last Traded Price

₹ 2,260 3.0%

1,843

2,297

Company Overview

Sales

16,468 Cr

Growth: 29.9%

Profit after Tax

1,065 Cr

Growth: 5.5%

Large Cap

63,782 Cr

P/E: 59.9x

Industry P/E: 28.0x

Fundamentals

Sales (Cr)	₹ 16,468
Growth	29.9%
EBITDA	26.5%
P/S	3.9x
Dividend	0.2%
P/E	59.9x
Book Value	₹ 351
PEG Ratio	2.0x
ROE	11.5%
P/B	6.4x

Shareholding Pattern

Institutions

Qualified Institutional Buyer

4.74 %

Hsbc Pooled Investment Fund - Hsbc Pooled Asia Pac

3.25 %

Hdfc Trustee Company Ltd. A/C Hdfc Growth Opportunities Fund

2.26 %

Ntasain Discovery Master Fund

2.05 %

Life Insurance Corporation Of India

1.76 %

Promoters

Saldanha Family Trust

45.45 %

Blanche Elizabeth Saldanha

0.39 %

Glenn Mario Saldanha

0.35 %

Cherylann Maria Pinto

0.27 %

Robin Joseph Pinto

0.18 %

Others

Ashish Dhawan

1.81 %

Iepf

0.08 %

Increase Decrease No change

Company Profile Detailed

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The Company is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products.

Belongs to (42 Indices) view more

Investors (111)

credit.s...

tata.bal...

oppeheim...

Followers (37)

nitin2

keerthi

deepak